Surgery in invasive pulmonary aspergillosis (IPA): indication and risks
| Indication for Surgery | Localiszed or multilocular IPA | |
| Early stage IPA | ||
| Failure of antifungal therapy | ||
| Planned immunosuppression, e.g. HDC or SCT | ||
| Haemoptysis | ||
| Perioperative mortality | 14% | (24 of 165 patients) |
| Postoperative complications | 7% | (12 of 165 patients) |
| (nonfatal) | ||
| Recurrent mould infection | 16% | (27 of 165 patients) |
| Fungal relapse post SCT | 8% | (3 of 35 patients) |
HDC: high dose chemotherapy
SCT: stem cell transplantation